Disappointing Trial Results For Athersys

Athersys Inc. (Nasdaq: ATHX) reported disappointing results from a mid-stage clinical trial of its refractory ulcerative colitis treatment MultiStem cell therapy. Shares of the biotechnology company plummeted $1.40 to close at $1.33.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.